Jaguar Health (JAGX) Cash from Investing Activities (2015 - 2025)
Jaguar Health (JAGX) posted quarterly Cash from Investing Activities of $13000.0 for Q4 2025, up 106.05% year-over-year from $6309.3 in Q4 2024, and up 106.05% quarter-over-quarter from -$215000.0 in Q4 2024.
Jaguar Health (JAGX) Cash from Investing Activities (2015 - 2025) Analysis & Trends
Jaguar Health (JAGX) has reported Cash from Investing Activities for 9 consecutive years, with $13000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 106.05% year-over-year to $13000.0; the TTM figure through Dec 2025 stood at -$202000.0 (up 6.05% YoY), while the FY2025 annual figure was -$41000.0, up 82.25% from the prior year.
- Cash from Investing Activities advanced to $13000.0 in Q4 2025 per JAGX's latest filing, from -$215000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $10.5 million in Q4 2021 and bottomed at -$10.5 million in Q3 2021.
- Historically, Cash from Investing Activities has averaged -$103166.7 across 4 years, with a median of -$135500.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 103.45% — and 2025, when it jumped 106.05%.
- Jaguar Health's Cash from Investing Activities stood at $10.5 million in 2021, then tumbled by 103.45% to -$361000.0 in 2022, then soared by 40.44% to -$215000.0 in 2024, then surged by 106.05% to $13000.0 in 2025.
- Business Quant data shows JAGX's Cash from Investing Activities at $13000.0 in Q4 2025, -$215000.0 in Q4 2024, and -$361000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2024 | -215,000.00 |
| Dec 31, 2024 | -215,000.00 |
| Dec 31, 2022 | -361,000.00 |
| Dec 31, 2022 | -361,000.00 |
| Sep 30, 2022 | -56,000.00 |
| Sep 30, 2022 | -56,000.00 |
| Dec 31, 2021 | 10.48 Mn |
| Dec 31, 2021 | 10.48 Mn |
| Sep 30, 2021 | -10.48 Mn |
| Sep 30, 2021 | -10.48 Mn |
| Mar 31, 2020 | -7,000.00 |
| Mar 31, 2020 | -7,000.00 |
| Mar 31, 2018 | -6,527.00 |
| Mar 31, 2018 | -6,527.00 |
| Dec 31, 2017 | -11,293.00 |
| Dec 31, 2017 | -11,293.00 |
| Sep 30, 2017 | -2.06 Mn |
| Sep 30, 2017 | -2.06 Mn |